WallStSmart

Abbott Laboratories (ABT)vsArtivion Inc (AORT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 9944% more annual revenue ($44.33B vs $441.33M). ABT leads profitability with a 14.7% profit margin vs 2.2%. ABT appears more attractively valued with a PEG of 1.52. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

AORT

Hold

39

out of 100

Grade: F

Growth: 6.7Profit: 4.5Value: 2.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
AORTSignificantly Overvalued (-2704.2%)

Margin of Safety

-2704.2%

Fair Value

$1.43

Current Price

$36.12

$34.69 premium

UndervaluedFair: $1.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

AORT1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.2%8/10

19.2% revenue growth

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

AORT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.7%3/10

ROE of 2.7% — below average capital efficiency

Profit MarginProfitability
2.2%3/10

2.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : AORT

The strongest argument for AORT centers on Revenue Growth. Revenue growth of 19.2% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 172.0x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

ABT profiles as a value stock while AORT is a growth play — different risk/reward profiles.

AORT carries more volatility with a beta of 1.64 — expect wider price swings.

AORT is growing revenue faster at 19.2% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

Want to dig deeper into these stocks?